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Animals store most excess energy as fat in specialized cells called adipocytes which 
form the major part of adipose tissue. Since obesity, which has reached epidemic 
proportions in the last decades, is the result of excess growth of the adipose tissue 
caused by both hypertrophy and hyperplasia, understanding how adipocytes expand is 
an important area research. Adipogenesis, the development of progenitor cells to 
mature adipocytes, has been widely studied with mouse models and in particular with 
differentiation of the murine preadipocytes 3T3-L1 and 3T3-F22A. Previous research 
has found Mitogen Activated Protein kinase (MAPK) activity to be required in the 
early stages of adipogenesis. MKPs are phosphatases with MAPKs as their substrate. 
They are known to dephosphorylate MAPKs in several tissues. MKP1 has been 
shown to have a role in adipogenesis as it can regulate phosphorylation of the MAPK 
ERK in differentiating 3T3-L1 cells. Previous findings in our group have shown 
many MKPs to be regulated at the mRNA level during 3T3-L1 differentiation; one of 
these, MKP5, has been shown to enhance adipocyte differentiation when ectopically 
expressed. In this study we found that one of the other MKPs, Vaccinia H1-related 
(VHR) phosphatase is regulated during adipogenesis. We also validate the integrity of 
two kinds of expression vector constructs created for three MKPs (VHR, MKP6 and 
VH5) all of which have been shown to be regulated during adipogenesis. The vector 
constructs for VHR were used in characterization of its potential role in 
differentiation of 3T3-L1 cells. These results further underscore the importance of 
MKPs in adipogenesis and pave the way for future studies. 
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1.1 Adipose tissue 
Animals store most excess energy as fat in the form of triacylglycerol (TG). Most TG 
is stored in specialized cells, called adipocytes, which are the main cell type of 
adipose tissue. Although there are differences among species, the basic concepts of 
adipose anatomy and physiology are similar between the commonly studied small 
rodents and less studied larger mammals, including humans [1].  
The adipose tissue is a loose connective tissue organized in separate depots. Each 
depot has their own supply of blood vessels, lymph nodes and nerves. The adipose 
tissue is separated into two main groups. Visceral adipose tissue is located inside the 
thorax and abdomen in relation to other organs while the main subcutaneous depots 
lie in the anterior and posterior part of the body. Subcutaneous adipose tissue in 
humans is less area specific as it is spread as a continuous layer beneath the skin. 
There are also apparent differences in adipocyte location between sexes as males tend 
to have more adipose tissue in the abdominal area and females have more developed 
mammary and gluteofemoral subcutaneous adipose tissue. In average, females also 
have a slightly higher adipose body percentage than men, 1(4-28% vs. 8-18%) [1].  
Adipose tissue can be divided into two main types, white and brown adipose tissue, 
(WAT and BAT, respectively). They are discussed briefly below. 
Brown adipocyte tissue 
Brown adipocytes have a multilocular distribution of TG droplets and a vast number 
of specialized mitochondria which contains the uniquely BAT expressed protein, 
uncoupling protein-1 (UCP1). The main physiological role of BAT is thermogenesis 
which is believed to be TG fueled heat production through UCP-1 driven 
mitochondrial combustion of substrates uncoupled from the production of ATP [2]. In 
small and young endothermic animals, with high surface to volume body ratio and 
less heat generation from muscle movement, BAT is more abundant and expresses 
more UCP-1 than in larger mammals. 
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White adipocyte tissue 
The WAT consists mainly of mature white adipocytes, but stromal vascular cells 
(including preadipocytes, fibroblasts and macrophages) can constitute up to 50% of 
the cellular content [3]. Preadipocytes are fibroblast-like cells determined to the 
adipocyte cell lineage. As mature adipocytes cannot proliferate, these cells function 
as source for new adipocytes in tissue turnover or expansion [4, 5]. The monocyte 
derived macrophages mainly remove foreign particles and dead cells in the adipose 
tissue, as well as initiating the immune response after an infection [6]. Lately the 
stromal vascular portion of the adipose tissue has been shown to contain cells that are 
able to undergo adipogenic (fat), osteogenic (bone), chondrogenic (cartilage), and 
myogenic (muscle) differentiation in vitro [7, 8]. Whether this is an indication of the 
presence of a multipotent stem cell within the tissue or only reflect the presence of 
several progenitor cells are still unclear. 
1.2 Adipocyte function  
1.2.1 Lipid metabolism 
The main functions of adipocytes are uptake and release of free fatty acids (FFAs) 
and glucose from the extracellular matrix, lipogenesis (TG synthesis) and lipolysis 
(TG hydrolysis). Figure 1 gives an overview of the key steps and regulation pathways 
of these processes. Up to 85% of a white adipocyte consists of TG [3], which usually 
is located in a unilocular vacuole called a lipid droplet emphasizing the importance of 
lipid metabolism in the cell. 
Hydrolysis of TG in the adipocytes leads to the release of FFA and glycerol into the 
bloodstream. FFA serves as a source of energy and glycerol is transported to the liver 
for reuse [9]. The rate limiting step in TG release is the hydrolysis of TG mediated by 
adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) that 
hydrolyze TG and diacylglycerol (DG), respectively. HSL translocates to the TG pool 
of the cell when phosphorylated directly by protein kinase A (PKA), a cyclic AMP 
(cAMP) activated kinase. The phospho protein perilipin A also moves to the TG pool 
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upon phosphorylation by PKA. Here it activates ATGL by a yet uncharacterized 
mechanism [10]. The rise in cAMP levels leading to PKA activation and hence 
lipolysis is positively regulated by adenylyl cyclase (AC) and is negatively regulated 
by phosphodiesterase (PDE). Activation of AC, generating cAMP from ATP, 
happens through a stimulatory G-protein (GS) which binds to the adrenergic receptor 
beta (ARβ). This activation of AC can be countered by an inhibitory G protein (GI) 
transmitting a signal from ARα2. In adipocytes the PDE isoform 3B negatively 
regulates cAMP leves by converting it to AMP. Tumor necrosis factor alpha (TNFα) 
negatively regulates both PDE3B expression and activity through its pathway 
(addressed in 1.4). In addition TNFα inhibits the action of GI on AC [11]. Insulin 
inhibits PKA action through PDE3B activation (see below).   
After a meal there is a switch in adipocyte biology from release of FFA to uptake and 
TG synthesis. FFAs are either synthesized de novo from glucose or recycled from the 
cytosol and extracellular fluid. Lipoprotein lipase (LPL) expressed on the surface of 
endothelial cells in the adipose tissue hydrolyzes circulating TG to FFA. FFA 
transport into adipocytes is mediated by fatty acid transporter proteins (FATPs). 
Imported FFAs are chaperoned by adipocyte fatty acid binding protein P2 (aP2) for 
re-esterfication and conjugation to coenzyme A (coA) catalyzed by acyl CoA 
synthetases (ACS) [12]. Both de novo synthesized FFA and recycled FFA are joined 
with G3P (3-glycerol phosphate) to produce TG [13].  Adipocytes lack the 
glycerokinase protein and cannot recycle glycerol for the lipolysis process. Therefore, 
glucose is the main source of G3P for the adipocyte [14].  
Insulin, a hormone secreted from pancreatic β cells, is a key factor in regulation of 
adipocyte lipid metabolism and glucose uptake. Insulin levels rise in fed state and fall 
in fasting [15]. Insulin acts mainly through insulin-like growth factor insulin receptor 
(IGF-IR) and insulin receptor (IR). IGF-IR transduces activation of Ras and protein 
kinase B (PKB) downstream pathways, while IR mediates signaling on IR substrate 
1(IRS-1) subsequently activating phosphatidylinositol-3 kinase (PI-3K) and also PKB 
[16]. Insulin promotes TG synthesis by initiating translocation of FATP1 and FATP4 
and glucose transporter 4 (GLUT4) from intracellular vesicles to the plasma 
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membrane, increasing the imported FFA and glucose needed for lipogenesis [17]. 
Insulin also inhibits lipolysis by phosphorylation and activation of PDE3B mediated 
by PKB [11]. 
 
 
Figure 1. Overview of the main pathways in adipocyte lipid metabolism. Reprinted, with permission from 
“Subcutaneous fat in normal and diseased states” by Avram, Avram et al. in journal for American Academy of 
Dermatology (2005) [9].  
The basics for the fat storage and metabolism in the adipocyte have been known since 
the 1970s. However, the adipocyte gained much more attention after the surprising 
discoveries in the 1990s made it clear that white adipocytes also act as an endocrine 
organ playing a major part in the systemic regulation of energy balance by release of 
adipocyte specific hormones called adipokines. Below, details about the most 
common adipokines are discussed. 
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1.2.2 Endocrine action of the adipocyte 
Leptin 
The best characterized adipokine was cloned in 1994 and identified as the product of 
the ob gene responsible for genetic obesity in deficient mice (ob/ob mice) [18]. 
Shortly after it was given the name leptin after “leptos” Greek for thin, as injections 
of a recombinant form of the protein reversed obesity on ob/ob mice [19]. When 
secreted from adipocytes and released into the blood leptin acts on many tissues and 
induces effects on muscles, bones, pancreatic beta cells, immune cells and also 
several other tissues and organs. However, the most important effect is believed to be 
on the Central Nervous System (CNS). Leptin is transported across the blood brain 
barrier (BBB) to reach the CNS and the hypothalamus where it targets two 
populations of neurons. Activation of neurons promoting energy expenditure and 
weight loss containing pro-opiomelanocortin (POMC)/cocaine and amphetamine-
regulated transcripts and inhibition of different neurons promoting food intake and 
weight gain expressing neuropeptide Y (NPY)/agouti-related peptide (AgRP), the 
latter group of neurons being suppressors of the former. Leptin signals through the 
leptin receptor (OB-Rb) which activates JAK/STAT (Janus kinase/Signal Transducer 
and Activator of Transcription) signaling among other pathways [13, 20]. 
Hepatocytes, adipocytes, heart, β cells of the pancreas and immune cells express the 
OB-Rb. Paracrine effects of leptin have shown importance in regulating oxidation of 
lipids and preventing ectopic lipid accumulation [21, 22]. Except fat mass, many 
other factors influence leptin levels: insulin, glucocorticoids, TNFα, estrogens and 
C/EBPα (CCAAT/Enhancer Binding Protein alfa) all increase leptin expression and 
secretion; conversely, β3-adrenergic activity, androgens, FFA, growth hormone (GH) 
and Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonists leads to 
decreased leptin levels [23]. 
Adiponectin 
Adiponectin is a protein that belongs to the collagen superfamily. It is uniquely 
expressed and secreted by mature adipocytes, especially in subcutaneous adipose 
tissue, and in extremely high concentrations. Adiponectin accounts for ~0.01% of all 
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serum proteins. In contrast to leptin, adiponectin levels are reduced with obesity and 
elevated during starvation. Adiponectin impacts body metabolism by increasing 
insulin sensitivity in metabolic tissues, such as muscle, adipose tissue and liver. In 
muscles it binds to Adiponectin Receptor 1 (AdipoR1) and promotes glucose uptake 
and FFA oxidation; in liver it binds AdipoR2, promotes FFA oxidation and decreases 
gluconeogenesis (the generation of 3-glycerol phosphate from precursors other than 
glucose) [24]. Downstream signaling of AdipoR1 is not well characterized, but is 
known to involve activation of p38 mitogen activated protein kinase (MAPK) and 
PPARα. Aside from metabolic effects, adiponectin executes anti-inflammatory 
effects through inhibition of NF-κB signaling and induction of several inflammatory 
cytokines in human monocytes, macrophages and dendritic cells [25, 26].  
RBP4 
Retinol binding protein 4 (RBP4) is a plasma transport protein for retinol and is up-
regulated in adipose tissue in mice deficient in GLUT4. RBP4 is elevated in obese 
and obese-diabetic human and mice, and overexpression of RBP4 in mice leads to 
increased insulin resistance [27]. RBP4 secretion by adipose tissue is suggested to be 
a reponse to low glucose blood levels detected by GLUT4. RBP4 suppresses insulin 
signals in muscles inhibiting the activity of PI-3K and IRS-1 phosphorylation, while 
increasing the glucose production in the liver increasing plasma glucose 
concentration [25, 27].    
Visfatin  
Visfatin, originally identified as pre-B-cell colony-enhancing factor (PBEF) that is 
expressed in bone marrow, liver and muscles over a decade ago, has been re-
identified in adipose tissue as a factor that is up-regulated during development of 
obesity. The visceral tissue specificity of visfatin is still controversial, and its 
supposed role in binding and activation of the insulin receptor need further proof, but 
its connection to adiposity is still strong [28-30].     
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PAI-1 
Plasminogen Activator Inhibitor-1 (PAI-1) regulates the coagulation cascade as an 
inhibitor of fibrinolysis and inactivation of urokinase-type and tissue-type 
plasminogen activator. PAI-1 also has proposed roles in atherogenesis and 
angiogenesis. PAI-1 is expressed in many cell types within the adipose tissue and its 
levels correlate with visceral adiposity [23, 31]. 
MCP-1 
Monocyte chemoattractant protein 1 (MCP-1) is involved in recruiting monocytes 
and T lymphocytes to sites of injury and infection. This chemokine is expressed in 
multiple cell types including endothelial, skeletal- and smooth muscle cells as well as 
adipocytes. The target of MCP-1 is chemokine CC motif receptor 2 (CCR2).  
Expression of MCP-1 rises with obesity in most fat tissue types, especially in visceral 
fat. In 3T3-L1 cells, insulin, TNFα, GH and IL-6 all induce MCP-1 expression [32, 
33]. 
1.3 Adipose tissue and obesity 
During the last three decades the prevalence of obesity in the United States have 
doubled for adults (from 15.2% to 30.4%) and children (from 6.5% to 15.8%) and 
tripled for adolescents (from 15.0% to 16.1%)[34]. The same trend is also seen in 
Norway and the rest of the world [35, 36]. Estimates suggest that worldwide 400 
million people are currently obese [37].   
Adipocity in humans is measured by the BMI index which is defined by the body 
mass in kgs divided by the square of height in meters. People with BMI of  ≥ 30 are 
considered obese [37]. Obesity is correlated with insulin resistance, type 2 diabetes 
and multiple cardiovascular diseases [38, 39]. Besides personal health problems, a 
population increased in obese individuals will thus face considerable increased costs 
in health care expenditures [40, 41]. 
Genetics do contribute to obesity [42], but an individual cannot become obese 
without having chronically greater energy intake than expenditure. Energy 
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expenditure includes physical activity, all voluntary movement, basal metabolism, all 
vital biochemical processes in the body; adaptive thermogenesis, and heat production 
generated to cope with climate [43]. Greater energy intake without increasing 
expenditure will increase TG storage in adipocytes which therefore will expand. 
Depending on net positive energy intake and genetic make-up of the individual the 
expansion of the fat tissue in extreme cases of obesity can reach 60 to 70% of total 
body mass in contrast to the normal 20%. This expansion is governed by enlargement 
of existing adipocytes (hypertrophy) and differentiation of preadipocytes into 
adipocytes (hyperplasia) [1, 42].  
The exact processes causing the health risks associated with increased fat tissue is 
still somewhat unclear. Dys-regulation in adipose metabolism and an interaction 
between the immune system and adipose tissue seem to stand central in this regard. 
Leptin levels rise with adiposity to promote energy expenditure and prevent plasma 
lipid accumulation. The effects of leptin, however, diminish with higher levels as 
tissues affected by leptin through its OB-Rb, develop resistance. The resistance is 
thought to be mediated in two ways: leptin action on the CNS is lost by impaired 
transport across the BBB, and the general OB-Rb signaling is inhibited by suppressor 
of cytokine signaling 3 (SOCS3) that acts as an intracellular negative feedback 
pathway from JAK/STAT activation [20, 21]. SOCS3, however, also inhibits IRS-1, a 
downstream signal of insulin action, hence leptin can contribute to insulin resistance 
[44]. In addition, leptin acts as a pro-inflammatory signal on the innate and adaptive 
immune system and in that way be a possible mediator of increased immune reaction 
to obesity [31].  
Both hypertrophy of the adipocyte and increasing levels of cytokines (addressed 
below) contribute to the increased lipolysis and stunted TG synthesis in the adipose 
tissue that is linked to obesity. The elevated plasma levels of FFAs are thought to 
have an especially important role in whole body insulin resistance as it inhibits 
insulin signaling, glucose uptake and glucagon synthesis in the muscles, and 
promotes glucose production in the liver [45, 46].  
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Two factors secreted by adipose tissue, TNFα and IL-6 (Interleukin 6), are both 
important pro-inflammatory cytokines [26]. Adipose tissue contributes up to a third 
of the circulating levels of IL-6. But considering its levels within the adipose tissue, 
which are 100 times higher than the circulation, IL-6 para- and autocrine functions 
have been more studied. During obesity IL-6 levels rise. Importantly, non-fat cells are 
the main secretors [47]. IL-6 promotes insulin resistance by inducing SOCS3 and 
lipolysis and by inhibition of adipogenesis and adiponectin secretion [47, 48]. IL-6 
have also been suggested to have a role in the early stages of arteriosclerosis [49]. 
The increasing levels of TNFα correlated to obesity are mainly secreted by 
macrophages accumulating in adipose tissue [49]. Indeed, in lean individuals 
macrophages contribute to 5-10% of the total cells in adipose tissue while in obesity 
this can increase up to 50% [50]. TNFα binds to the TNF receptor and activates the c-
Jun N-terminal kinase (JNK) pathway and/or nuclear factor κB (NFκB) through 
activation of inhibitor of NF-κB (IκB) kinase (IKKβ). Increased JNK activity in 
obesity leads to fortified insulin resistance as IRS-1 activity is decreased [51]. TNFα 
affects the expression of several adipokines with central roles in mediating the health 
risks associated with obesity; adiponectin levels decrease, leptin increase, more FFAs 
are released, circulating PAI-1 levels are elevated, and more MCP-1 is secreted [23, 
32, 49]. 
A major factor promoting the macrophage migration to the adipose tissue during 
increased obesity is MCP-1. In addition to the factors leading to increased MCP-1 
secretion mentioned above, hypertrophied adipocytes release more MCP-1 [52]. 
Other than the role in mediating a low grade chronic inflammation of the adipose 
tissue [44], MCP-1 increase insulin resistance and its elevated plasma levels are 
linked to development of atherosclerosis [50]. 
Hyperplasia and hypertrophy are necessary for the adipose expansion [1]. Since 
mature adipocytes do not undergo mitotic expansion [53], understanding the 
mechanisms of adipocyte development from precursor cells are important and may 
provide clues as to how to manage the increasing obesity epidemic. 
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1.4 Adipose development 
Adipocytes are considered to derive from the mesoderm germ layer, although 
questions have been raised whether mesodermal tissue is the only possible origin for 
adipocytes [42, 54]. The mesenchymal stem cells (MSCs) were first identified in 
human bone marrow and are used as a cell model for mesoderm tissue [42]. Both in 
vitro and in vivo studies have found MSCs to be capable of differentiating into a 
range of cell types including chondrocytes, adipocytes, myocytes, cardiomyocytes 
and bone marrow stromal cells [55]. The steps in differentiation of MSCs have been 
less characterized as they are indistinguishable from fibroblasts morphologically, and 
although some cell markers that can distinguish MSCs from other cells have been 
identified, no markers for distinct steps during early development have been found 
[56]. There has been some success in determining factors and pathways affecting the 
early development of MSCs. In the differentiation program towards the adipocyte 
lineage stimulation by bone morphogenic protein 2 and 4 (BMP2/4) can commit 
multipotent cells to adipocyte lineage and/or augment their adipocyte differentiation, 
through both Small mothers against decapentaplegic (Smad)- and p38-dependent 
mechanisms [57]. Tumor growth factor beta (TGF-β) inhibits adipocyte 
differentiation by inactivating C/EBP transcription factors via physical interaction 
with Smad3 [58]. In addition transcription factor activation through Wnt signaling 
have been found activate the early events of adipogenesis [59]. 
The mouse preadipocyte cell-lines 3T3-L1 F422A and 3T3-L1 have been widely used 
as model systems to study adipogenesis. These cells have the morphology of 
fibroblasts, but are committed to the adipocyte lineage [42, 60]. Below sections 
review the key steps in the differentiation of 3T3-L1 cells to a mature adipocyte.   
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1.4.1 Adipogenesis 
Differentiation of a preadipocyte into a mature adipocyte is commonly divided into 3 
stages: growth arrest, mitotic clonal expansion (MCE), and terminal differentiation 
[61] (depicted in Figure 2). Growth arrest of the preadipocytes (in G0/Gi phase) 
occurs by contact-inhibition. At this point addition of prodifferentiative hormones 
will signal the arrested preadipocytes to re-enter the cell cycle and undergo several 
rounds of cell division, known as the MCE. There has been some controversy 
whether the MCE is required for differentiation [61]. Following the MCE, 
preadipocytes enter a unique growth arrested stage, GD (D for differentiation), 
considered to be a poorly defined point of no return for commitment to terminal 
differentiation. During terminal differentiation 3T3-L1 cells transform from their 
fibroblastic morphology into the appearance associated with mature adipocytes, with 
a round shape and lipid filled vacuoles, as well as with their biochemical 
characteristics [53]. 
 
Figure 2. Temporal expression of the major transcription factors involved in differentiation of 
preadipocytic cell lines. See the text for more details. Thick line, higher expression level; thin line, lower 
expression level. Reprinted, with permission, from the Annual Review of Nutrition, Volume 20 ©2000 by 
Annual Reviews www.annualreviews.org [62]. 
Below is a review of the most important transcription factors (TFs) that have a role in 
differentiation of preadipocytes.  
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1.4.2 PPARγ 
The Peroxisome Proliferator-Activated Receptor (PPAR) belongs to a family with 
three members, α, δ and γ forms, and is member of the nuclear hormone receptor 
(NHR) superfamily. PPARs heterodimerize with the retinoid X receptor (RXR) prior 
to DNA binding [63]. From the PPAR family, it is PPARγ which is relevant for 
adipogenesis [64]. Multiple FFAs and their derivates, as well as certain eicosanoids 
(e.g. the prostaglandin J2), act as low affinity ligands for PPARγ, but an endogenous 
PPARγ ligand has not been identified. Nevertheless, several synthetic agonists are 
available, e.g. the thiazolidinediones (TZD) which are used in the clinic as insulin 
sensitizers [64]. PPARγ is responsible for activating many, if not most, of the genes 
involved in adipose tissue associated processes: fatty acid binding, storage and 
metabolism, and gluconeogenesis; e.g. aP2, LPL and acyl-CoA oxidase (ACO), 
which catalyze the first step in fatty acid β oxidation [65]. Three isoforms of PPARγ 
have been identified, γ1-3, γ1 and γ3 code for the same protein product but from 
different transcripts and are ubiquitously expressed while PPARγ2 is unique to the 
adipose tissue. The specific role of the different isoforms during adipogenesis is still 
unclear [61, 66]. The important role of PPARγ in adipocyte differentiation has been 
demonstrated through multiple experiments including in vitro overexpression and 
knockdown, as well as in vivo gene targeting in mice [67-71]. Knowledge drawn 
from these experiments, emphasize PPARγ as necessary and sufficient for 
adipogenesis. 
1.4.3 C/EBP family 
C/EBPs (CCAAT/Enhancer Binding Protein) is a family of six (α, β, γ, δ, ε and ζ) 
highly conserved transcription factors, containing a leucine zipper domain involved 
in dimerization and DNA binding. In adipocytes, three members of the family are 
implicated as positive regulators of adipogenesis; C/EBPα, C/EBPβ, and C/EBPδ 
[72]. C/EBPα acts as a promoter for many adipocyte genes such as GLUT4, leptin 
and aP2 [73]. Studies in fibroblasts lacking PPARγ found that C/EBPα alone is 
unable to induce differentiation, suggesting that C/EBPα and PPARγ participate in 
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the same pathway [74]. C/EBPα has been linked to different features of adipogenesis, 
such as growth arrest, insulin sensitivity and promoting the expression of PPARγ and 
own gene through differentiation [75-78]. 
C/EBPβ and C/EBPδ are expressed early after induction of adipogenesis [79]. 
Ectopic expression of C/EBPβ, but not C/EBPδ alone, has proven to be sufficient to 
induce differentiation in vitro [79-81]. In defining the order of actions towards 
terminal differentiation recent studies have shown that C/EBPβ, but not C/EBPα, 
induces PPARγ expression in the absence of PPARγ or PPARγ ligand. This leads to a 
model showing early induction of C/EBPβ and C/EBPδ after induction of 
differentiation, which activate expression of PPARγ. PPARγ, possibly concert with 
C/EBPβ and C/EBPδ, then facilitates C/EBPα expression [82]. C/EBPβ is induced by 
cAMP levels through CREB [83]. DNA binding of C/EBPβ at the centromeres seems 
to be pre-required for initiation of MCE [84, 85].  
Two other members of the C/EBP family, CHOP-10(C/EBPζ) and C/EBPγ, have 
been suggested as inhibitors of adipogenesis. They heterodimerize with C/EBPβ 
causing its inactivation and disrupt its DNA binding [73]. 
1.4.4 KLF 
Another group of transcription factors regulating adipogenesis is KLF (Krüppel Like 
Factors). Several members of this large C2H2-zinc finger family play a role during 
adipocyte differentiation. KLF2 binds the promoter of PPARγ2 and represses its 
activation, thereby inhibiting adipogenesis [66, 86]. After induction of differentiation, 
expressed KLF5, induced by C/EBPβ and C/EBPδ, dispatch KLF2. This promotes 
PPARγ2 expression. Later in development KLF5 is downregulated and expression of 
the proadipogenic KLF15 increases. KLF15 also promotes PPARγ2 expression in 
addition to promoting expression of genes associated with mature adipocytes (e.g. 
GLUt4) [87]. Other KLFs that have been shown to act in adipogenesis are KLF7, 
KLF6, KLF3 and KLF4. KLF4 has been shown to be induced in response to cAMP 
and in cooperation with KROX20, which is a proadipogenic factor [88], that 
promotes expression of C/EBPβ [66, 89, 90].  
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1.4.5 Other factors invoved in adipogenesis 
ADD1/SREBP-1c belongs to a transcription factor family known to regulate genes 
important in cholesterol and fatty acid metabolism, SREBP (Sterol Regulatory 
Element Binding Protein). ADD1/SREBP-1c is expressed early after induction of 
adipogenesis and activated by insulin action [91].  Expression studies have indicated 
that ADD1/SREBP-1c promotes secretion and/or synthesis of natural ligand for 
PPARγ independent of the C/EBPβ pathway [92, 93]. 
The E2F (adenovirus E2 promoter binding factor) transcription factor family is 
essential in regulating the cell cycle. E2Fs seem to play their main function in the 
transition from growth arrested preadipocytes into the MCE as free E2F/DP 
heterodimers or in complexes with pocket family proteins (pRB, p107, p130) and 
cyclin/cdk protein family members. E2F4 and 5 act as repressors, and when active, 
prevent progression into MCE. E2F1-3 act as activators and E2F1 induces PPARγ 
transcription during MCE [94]. 
The zinc finger transcription family GATA has its name from the consensus sequence 
which they recognize. Out of the 6 GATA proteins, GATA2 and GATA3 are 
expressed in adipocytes [95]. These inhibit adipogenesis by interacting with C/EBPα 
and β as well as suppressing expression of PPARγ by acting on its promoter [96]. 
FoxA2 and FoxO1, members of the forkhead box protein family, are both thought to 
have inhibitory effects on adipocyte development prior to and in the early stages of 
differentiation. FoxA2 inhibits adipogenesis by preventing the downregulation of 
Pref-1, Gata-2, and Gata-3 (Pref-1 being a marker for preadipocytes and anti-
adipogenic factor) [97, 98], and FoxO1 by preventing MCE as its associated with 
increased expression of cell cycle inhibitors [99].   
STAT (Signal Transducers and Activators of Transcription) are a family of seven 
members (STAT1-4, 5A, 5B, 6). STATs are activated through tyrosine 
phosphorylation by Janus kinases (JAKs) that respond to signals form a family of 
cytokine receptors that are activated by a range of growth factors, hormones and 
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cytokines. During differentiation in 3T3-L1 cells, expression of STAT1, STAT3 and 
STAT5 has been observed. The mechanisms of STATs action on adipogenesis is still 
unclear [100]. Recent studies have pointed out STAT3 as an anti-adipogenic factor 
[101], and STAT5, in particular STAT5A, as a pro-adipogenic factor [102, 103]. 
Extracellular signals exert their effects either by a direct impact on transcription 
factor expression levels or by affecting their activity, e.g. through co-factor 
recruitment and/or modification. One widely used modification in the cell in response 
to extracellular ques is phosphorylation through kinase pathways. A major kinase 
pathway in the cell, MAPKs, has a role in adipogenesis and is further discussed 
below.   
1.5 MAPK signaling pathway 
1.5.1 General structure and function 
The mitogen activated protein kinases (MAPKs) are ubiquitously expressed, highly 
conserved serine/threonine kinases and involved in pathways controlling 
embryogenesis, cell differentiation, cell proliferation and cell death [104, 105]. In 
mammals 14 MAPK genes identified to date have been grouped in 7 distinct families 
based on a motif in their activation loop and activation pathway: extracellular signal-
regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 1-3(JNK1-3), p38 (α, β, γ, δ), 
ERK5, ERK3/4, Nemo-like kinase (NLK) and ERK7, the four former being 
considered the main families and will be the ones referred to from now on [105-107]. 
The three MAPK families share a threonine-X-tyrosine motif within their active loop. 
Both the threonine and tyrosine residues need to be phosphorylated to activate the 
MAPK. Highly specific MAPK kinases (MAP2Ks) phosphorylate the MAPKs. The 
MAP2Ks are under activational control by MAP2K kinases (MAP3Ks), giving a 
three step phosphorylation cascade transducing signals from numerous stimuli, 
including growth factors, mitogens, inflammatory cytokines and cellular stress. 
Activated MAPK phosphorylates cytosolic targets and translocates into the nucleus to 
execute its actions on gene expression. The final actions of the MAPKs depend on 
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several features of the phosphorylation cascade. Amplification of the signal can be 
achieved when the substrate kinase is more abundant than the activated kinase. 
Furthermore, with overlapping substrate specificity among the MAPKs the pathways 
have integrated responses. Another interesting future of the MAPK cascade is the 
scaffold proteins and docking motifs on the MAPKs which assure fast and accurate 
signal transfer and are also target of pathway regulation [105].  
Figure 3 gives a simplified overview of the different pathways of the MAPK cascades 
and their functions. The cellular responses to the MAPK are in large part mediated by 
downstream phosphorylation of a variety of transcription factors, for reviews, see 
[105, 108]. 
 
Figure 3. A schematic overview of the main MAPK family pathways. For details see text below. Reprinted, 
with permission from “Concise review: regulation of embryonic stem cell lineage commitment by mitogen-
activated protein kinases” by Binetruy, Heasley et al. Stem Cells (2007) [109]. 
The ERK pathway is mainly associated with promoting cell growth, cell proliferation 
and cell survival in response to mitogens and growth factors. Ras, a small GTPase, 
transmits most extracellular signals through activation of the Raf MAP3K family. 
The Rafs subsequentially phosphorylate MEK1/2, the upstream activators of ERK, 
 23
that in turn phosphorylate ERK at the threonine-glutamate-tyrosine motif which 
results in ERK activation [105, 110].  
JNK, also called the stress activated MAPK (SAPK), is activated by phosphorylation 
of the Threonine-Proline-Tyrosine motif and mediates response to various stress 
stimuli (e.g. UV-light, heat, osmotic shock), inflammatory cytokines (IL-6, TNFα) 
and growth factors. MKK4 and MKK7 are the upstream MAP2Ks for JNK. MKK7 
mainly mediates cell responses to cytokines while MKK4 is activated by stress; in 
addition to JNK, MKK4 also activates p38. Furthermore, MKK4 and MKK7 seem to 
preferentially phosphorylate JNK on tyrosine and threonine, respectively, indicating  
cooperative activation [111]. MKK4 and MKK7 activation is induced by a number of 
different  MAP3Ks, many shared with the p38 pathway [112]. In addition to 
influencing the inflammatory response, metabolism and cell transformation through 
activation of various transcription factors, JNK plays an important role in 
apoptosis/cell survival by inhibiting the antiapoptotic proteins Bcl-2 and Bcl-xl [111, 
113]. 
The pathway of p38 activation is highly integrated with the pathway of JNK and 
responds to similar stimuli. MKK3 and 6 are specific activators of p38 while MKK4 
is shared with JNK. They all activate p38 by phosphorylating the threonine-glycine-
tyrosine motif. As mentioned above JNK and p38 share most of the same MAP3K. 
p21 activated kinases (PAKs), however, seem to be exclusive for p38. Upstream of 
the MAP3K GTPases of the Rho family contribute to p38 activation. The 
downstream effects display great variety including inflammation, cell cycle 
regulation, cell death, senescence and tumorgenesis. These responses, however, seem 
to be specific with regard to cell type [107].    
ERK5, also known as big MAPK1 (BMKP1), shares activation motif with ERK but 
differs from it and the other two MAPKs as it is considerably larger (~88 kDa vs. 38-
54 kDa). Although sharing activation signal with all the other MAPKs, ERK5 
displays a narrow pathway specificity, being specifically phosphorylated by only the 
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MAP2K MKK5. Of the MAP3Ks, the MEKK family are the main transducers of 
signals [108]. 
1.5.2 MAPKs in adipogenesis 
ERK pathway was linked to adipogenesis in 1991 when it was shown that ectopic 
expression of an active Ras mutant led to growth arrest and terminal differentiation of 
3T3-L1 cells in the absence of insulin and IGF-1 [114]. Later inhibition of ERK 
expression was found to suppress adipogenesis [115]. However, in response to 
various growth factors, ERK has been shown to inhibit PPARγ activity by direct 
phosphorylation thereby suppressing adipogenesis [116, 117]. The seemingly 
incompatible findings that ERK could both induce and inhibit adipogenesis were put 
in context with a model for temporal regulation of ERK. The ERK pathway was 
found to be necessary for the MCE that is prior to terminal differentiation [118]. 
Another study showed ERK to be activated immediately after induction of 
differentiation inducing expression of transcription factors central in adipogenesis 
(C/EBPα and PPARγ), followed by a rapid inactivation [119]. Later the effect of 
ERK on C/EBPα and PPARγ expression has been linked to an activational 
phosphorylation of C/EBPβ [120]. In vivo studies with ERK1-/- knockout mice have 
indicated that ERK1 but not ERK2, is the isoform active in adipogenesis [121]. 
ERK1-/- mice are protected from insulin resistance and high fat diet induced obesity 
supporting the in vitro findings [122].    
As ERK, p38 and JNK show an induced activation immediately after induction of 
adipogenesis in 3T3-L1 cells [123]. Studies done with p38 inhibitors in 3T3-L1 cells 
have linked p38 activation to phosphorylation of C/EBPβ leading to its activation, as 
seen with ERK, and subsequent promotion of adipogenesis [124, 125]. Further 
evidence for p38 acting in a proadipogenic manner was shown by overexpression of 
active MKK6 [126]. This dominant active mutant was sufficient to induce activation 
without any hormonal stimulation. However, prolonged overexpression induced 
massive cell death. Two additional reports further support p38 as an enhancer of 
adipocyte development [127, 128]. In opposition to these results p38 has been found 
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to activate CHOP leading to inhibition of C/EBPβ [129, 130]. In addition, a study of 
p38 action in adipocyte development using multiple cell lines found that its 
knockdown and inhibition promoted adipogenesis. The authors suggested that cell 
line differences was the cause of variation [131]. 
Few roles have been pinned to JNK in adipogenesis, although JNK activation have 
shown to inhibit PPARγ [132]. JNK1 and JIP1 (JNK interacting protein 1) have been 
suggested a role in development of obesity, as deficiency of JIP1 mice and absence of 
JNK1 in ob/ob mice was linked to resistance to obesity [133, 134]. 
There is currently limited information on the possible role of ERK5 in adipogenesis. 
A recent study, have proposed a small role for ERK5 overlapping with the action of 
ERK in adipogenesis [135].  
1.6 MAPK Phosphatases  
1.6.1 General features 
The dual specificity phosphatases (DUSPs) also known as MAPK Phosphatases 
(MKPs) consist of a subfamily of the superfamily of protein tyrosine phosphatases 
(PTP) that can dephosphorylate both phospho-tyrosine and phospho-threonine. It is 
common to separate the MKPs in a group of typical MKPs and atypical MKPs, with 
11 and 19 family members, respectively [136]. All typical MKPs, except a 
catalytically inactive (DUSP24), regulate MAPK activity through dephosphorylation 
of the TXY-motif (Table 1). Several atypical MKPs have also been shown to have 
MAPK as substrate, discussed below [137].  
DUSPs have a catalytic dual specific phosphatase (DSP) domain at the C-terminus 
with the conserved motif HCXXXXXR (Histidine, Cysteine, X is any amino acid and 
Arginine) [138]. The DSP motif has no strict preference for any of the MAPKs, so 
typical MKPs have a MAPK binding (MKB) motif at the N-terminal end. This motif 
regulates specificity, but in the case of some MKPs also the activity as binding with 
the MKB motif induces catalytic activity by a conformation change [139].  
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The classification of MKPs has been done with emphasis on DNA or amino acid 
sequence similarity, protein structure, substrate specificity and/or subcellular 
localization resulting in differences in classifying the MKPs [138, 140, 141]. Table 1 
summarizes features of the typical MKPs, such as substrate specificity and 
subcellular localization.  












5q34 Nuclear JNK, p38, ERK 
Negative regulator of immune 
function. Protects mice from 
lethal endotoxic shock. Plays 
a key role in metabolic 
homeostasis and mediates 
resistance to cellular stress in 








None PAC-1 2q11 Nuclear ERK, p38 
Positive regulator of 
inflammatory responses. 









rVH6 12q22-q23 Cytoplasmic ERK 
Negative feedback regulator 
of ERK2 downstream of 
FGFR signaling 
DUSP7/ 
MKP-X Pyst2, B59 3p21 Cytoplasmic ERK Unknown 
DUSP9/ 
MKP4 Pyst3 Xq28 Cytoplasmic ERK>p38 
Essential for placental 





hVH5, HB5 11p15.5 
Cytoplasmic/
nuclear JNK, p38 Unknown 
DUSP10/ 
MKP5   1q41 
Cytoplasmic/
nuclear JNK, p38 
Functions in innate and 
adaptive immunity 
DUSP16/ 
MKP7   12p12 
Cytoplasmic/
nuclear JNK, p38 Unknown 
Table 1. Nomenclature, properties and physiological functions of dual-specificity MKPs. Reprinted, with 
permission from “Dual-specificity MAP kinase phosphatases (MKPs) and cancer” SM Keyse, Cancer 
Metastasis Review (2008) [142].   
Group I 
Members: DUSP1/MKP1, DUSP4/MKP2, DUSP2 and DUSP5. The MKPs of this 
group consist of 300 to 400 amino acid residues. A nuclear localization signal (NLS) 
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guides these MKPs to the nucleus where they are induced by many of the same 
stimuli as the MAPKs. Thus, they are suggested to be involved in negative feedback 
control of MAPK signaling [139]. The role of MKP1 is best characterized in 
regulation of immune function [143]. MKP1 deficient macrophages are sensitized in 
their response to bacterial lipopolysaccharides (LPS) through prolonged and elevated 
p38 and JNK activities, and display an increase in cytokine production [144, 145]. 
MKP1 also plays a role in the metabolic homeostasis, addressed below. 
Group II 
Members: DUSP6/MKP3, DUSP7/MKPX and DUSP9/MKP4. These MKPs have 
nuclear export signals (NES) and localize to the cytosol. These ~400 amino acid large 
MKPs display a preference for ERK dephosphorylation [141]. This group has 
especially been linked to early development. MKP4 knockouts in mice are embryonic 
lethal as the placenta fail to develop properly [146]. MKP3 is activated by fibroblast 
growth factor (FGF). Dys-regulation of MKP3 in mice gives a range of 
developmental issues (e.g. postnatal lethality, skeletal dwarfism and hearing loss) 
[147, 148].  
Group III 
Members: DUSP8/VH5, DUSP16/MKP7 and DUSP10/MKP5. These MKPs form a 
group of larger phosphatases, with VH5 and MKP7 ~650 amino acids and MKP5 
almost 500 amino acids [139]. They also have selectivity for p38 and JNK 
phosphorylation. VH5 and MKP7 have a domain rich in prolines, glutamates, serines 
and threonines (PEST), suggested to be involved in rapid turnover of the proteins 
[138, 149]. MKP5 have an identified function in the innate immune system. 
Macrophages lacking MKP5 show elevated JNK response to LPS stimulation. The 
elevated JNK activity leads to higher production of cytokines [150]. VH5 has been 
found to be expressed mainly in the adult brain, heart, and skeletal muscle [151-153].   
Atypical MKPs 
Five of the atypical MKPs have been found to dephosphorylate MAPKs: 
DUSP3/VHR, DUSP14/MKP6, DUSP18, DUPS22/VHX and DUSP26/MKP8. Of 
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these ~200 amino acid short MKPs VHR (Vaccinia H1-related) and MKP6 are the 
most studied [139]. VHR was the first DUSP identified in mammals [154]. In T cells 
it has been found to negatively regulate ERK and JNK activation [155]. The 
expression of VHR is not acutely induced, but VHR activity regulation has been 
found to be dependent on activators. Two have been identified: VRK3 and Zap-70 
[156, 157]. Recently VHR has been reported to play an important role in the 
regulation of cell cycle, as knockdown of VHR leads to cell arrest in G1/S and G2/M 
phase [158]. MKP6 have been suggested to act in a negative feedback loop on T cell 
CD28 co-stimulatory signal [159].  
1.6.2 MKPs in adipogenesis 
To date, only two MKPs have been reported to affect adipogenesis and adipocyte 
function, MKP1 and MKP4 [160, 161]. The effect of MKP1 on adipogenesis was 
tested with both 3T3-L1 and 3T3-F224A cells. It was found that altering the 
immediate, but usually transient, expression of MKP1 was associated with induction 
of differentiation [162-164], This indicates a role for MKP1 in regulating the 
essential down-regulation of ERK activity during adipogenesis [161]. MKP1 
knockout mice display resistance to diet induced obesity. The resistance was 
proposed to be an effect of lack of only MKP1 nuclear action and not cytosolic action 
as MAPK action in the cytosol seemed similar in wild type and knockout mice [165]. 
MKP4 has been found to block insulins negative control of the promoter of PECK 
(phosphoenol pyruvate carboxykinase) gene [166]. PECK is an important enzyme in 
glyconeogenesis. Further investigations of the same group showed that MKP4 was 
present in murine adipocytes and upregulated in ob/ob mice. In addition they found 
ectopically expressed MKP4 to inhibit adipogenesis and glucose uptake in 3T3-L1 
cells. In a very recent publication, MKP1 and MKP4 were indicated induced by 
dexamethasone in 3T3-L1 cells, and a concominant block of p38 was followed by a 
reduction in insulin-induced glucose uptake [160]. This suggests a role for MKP1 and 
MKP4 in insulin resistance.  
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2. Aim of the project 
ERK, p38 and JNK have active kinase activity during adipogenesis and important 
functional roles of ERK and p38 have been described [119, 123, 131]. Despite this 
information, the expression profiles of MKPs and whether they have a role in 
adipogenesis is poorly understood [160, 161, 165]. One exception to this is that 
MKP1 has been linked to regulation of ERK dependent MCP-1 secretion in 
hypertrophied 3T3-L1 cells [167].  
Previous work in our group (FS lab; Figure 5 and unpublished data) has found that 
mRNA levels of several MKPs are regulated during adipogenesis in 3T3-L1 cells. 
Three MKPs with interesting regulation profile from this analysis (VHR, MKP6, and 
VH5) were chosen for further study.   
The goals of this study were to: 
- Investigate if the mRNA regulation of VHR is also at the protein level.   
- Establish a stable 3T3-L1 cell line expressing MKPs under the control of a 
tetracycline induced promoter  





3. Materials and Methods 
3.1.1 Cell culture 
3T3-L1, COS-7 and BOSC cells (all ATCC) were cultured in standard medium 
[DMEM (Lonza) supplemented with standard 10% fetal bovine serum (FBS, PAA), 
50U/mL penicillin and 50µg/mL streptomycin (Cambrex), and 2mM L-Glutamine 
(Cambrex)]. The cells were kept at 37°C in a humidified 5% CO2, 95% air incubator 
(Forma Scientific). 60-80% confluent cells were passed in a 1:3/1:4 ratio. 3T3-L1 
cells stably expressing TETON were kept in standard medium with 500µg/mL 
Geneticin/G418 sulphate (Gibco). 3T3-L1 cells stably expressing TETON and TRE-
TIGHT His-VHR were kept in standard medium with 500µg/mL G418 and 
150µg/mL Hygromycin (Invitrogen). Tetracycline (Tc) depleted medium used with 
the TETON system, was standard medium supplemented with TET System Approved 
FBS (Clontech) instead of standard FBS. When using Tc depleted medium it replaced 
standard medium from the last passage before the start of the experiment. 1µg/mL 
doxycycline (dox, Sigma) was added to the media to induce expression of the 
TETON system.  
Differentiation of 3T3-L1 cells were induced two days after reached confluency. 
Cells were treated with a standard induction medium containing fresh serum, 1µM 
dexamethasone (Sigma), 0.5mM isobutylmethylxanthine (IBMX, Sigma) and 
5µg/mL insulin (Sigma)]. After 48 hours the medium was changed to standard 
medium containing 5µg/mL insulin. 
3.1.2 Oil Red O staining 
3T3-L1 cells were fixed with 0.5% gluteralaldehyd (EMS) in phosphate buffered 
saline (PBS), stained with Oil Red O solution [0.15% Oil Red O (Sigma) in 60% 
isopropanol (Arcus)] for 10-30 minutes (until precipitate was starting to form) and 
washed before picture was taken with camera (Nikon Coolpix 4500) directly (1X) or 
through microscope at 200X magnification (Nikon Elipse TS100).  
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3.1.3 Construction of expression plasmids  
The VH5 open reading frame was amplified from a pYX-Asc vector containing the 
VH5 cDNA (NM_008748) (ATCC) using AccuPrime Pfx DNA Polymerase 
(Invitrogen) with a standard PCR machine (PTC-200, MJ Research). The PCR 
program used was as follows: Enzyme activation/DNA denature step 95°C for 2 
minutes followed by 20 cycles: denaturing (95°C for 15 seconds), annealing (60°C 
for 30 seconds), extending (68°C for 2 minutes). The amplified PCR product was run 
on a 1% agarose gel to verify right size and extracted with QIAquick gel extraction 
kit (Qiagen). PCR product was cloned into pcDNA4/HISMAX TOPO vector 
(Invitrogen) and transformed into One Shot TOP10 chemical competent E.coli 
(Invitrogen). Ampicillin selected positive colonies were screened for VH5 insert 
using whole cell PCR and then sequenced. Mutation-free plasmid was isolated by 
MIDI prep (GENOMED). Figure 4A displays a vector map of pcDNA4/HISMAX 
VH5. 
The VH5 coding sequence was an amplified form of pcDNA4/HISMAX VH5 with 
primers that included the His-tag at 5´ sense end and a primer with overhang adding 
HindIII restriction site at 3´sens end. Amplification and isolation were done and the 
PCR-product was cloned into pcDNA4/HISMAX TOPO vector, followed by 
transformation, screening and sequencing as described above. From the new vector 
pcDNA4/HISMAX His-VH5 a segment containing a His-tag followed by the VH5 
coding sequence could be cut out using HindIII (NEB) restriction enzyme. The 
segment was ligated into the multiple cloning site (MCS) of HindIII cut pREVTRE-
TIGHT using T4 ligase (NEB) according to manufacturer`s instructions. Ligated 
vector was transformed into electro-competent DH10B E.coli and screened by 
restriction enzyme analysis. A positive clone was sequenced and confirmed to be 
mutation free. Figure 4B display vector map of pREVTRE-TIGHT His-VH5.  
All sequencings were performed by the in-house ABI lab core facility (Dept. 
Molecular Biosciences, University of Oslo, Norway). Sequence analyses were 
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performed with Sequence Scanner (Applied Biosystems) software for raw data 
analyses and Vector NTI Advanced 10 (Invitrogen) for alignment analyses. 
pcDNA4/HisMax VH5
























Figure 4. The VH5 vector constructs. A:  Vector product obtained from cloning the VH5 coding sequence 
into the pcDNA4/HISMAX TOPO vector. B:  Vector product obtained from cloning the His-VH5 sequence 
from pcDNA4/HISMAX His-VH5 into pREVTRE-TIGHT vector. 
Vector features: CMV, Human cytomegalovirus immediate-early enhancer/promoter; QBI SP163, 
translational enhancer; 6xHis, epitope of 6 repeted Histidines for His antibody; EK recognition site, 
Enterokinase recognition site (allows removal of N-terminal tag); Amp, gene for ampicillin resistance; pUC 
origin, allows high copy number in E.coli; BGH pA, Bovine growth hormone polyadenylation signal; TRE-
TIGHT modified TET-response element; Hyg, gene for hygromycin resistance; MoMuSV LTR, Moloney 
murine leukemia virus long terminal repeat; Extended Packaging Signal. 
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3.1.4 Transient transfection  
Cells were transfected with Fugene 6, a cationic lipid based transfection reagent 
(Roche). Cells were seeded 14-18 hours prior to transfection to reach ~60% 
confluency. Appropriate DNA and Fugene 6 reagent were mixed according to 
manufacturer’s instructions and incubated for 20-30 min. Cells were incubated with 
transfection mix for 10-12 hours before the media were changed and  incubated for 
48 hours. Transfections were done on 10 cm plates using 5µg vector DNA for 
samples to Western analyses and on 6 well plates using 1µg vector DNA for samples 
to qPCR. 
Transfection of 3T3-L1 cells prior to induction of differentiation was done first at 3 
days and then a second time 12 hours prior to induction. The second transfection was 
done because pilot experiments had shown that levels of ectopic expressed His-VHR 
diminish before the fourth day after transfection (data not shown) and we wanted to 
maintain the expression at least past the observed downregulation at day 4 and 6 in 
Figure 6B and C.  
3.1.5 β-gal staining   
β-gal staining was performed to check the efficiency of Fugene 6 transfections. Cells 
were transfected with pCMV β-gal (ATCC), treated with fix solution [2% 
formaldehyde (Sigma) and 0.2% gluteraldehyd in phosphate buffered saline (PBS)] 
and then incubated with histochemical stain [5mM potassium ferricyanide (Sigma), 
5mM potassium ferrocyanide (Sigma), 2mM MgCl2 (Sigma) and 1mg/mL X-gal 
(Saveen Werner)  in PBS] at 37C for 14-24 hours. The pCMV β-gal vector contains 
the gene for β-galactosidase under the regulation of the minimal cytomegalovirus 
(CMV) promoter. Cells expressing the vector would be able to catalyze X-gal to a 
blue byproduct. Picture was taken with camera. 
3.1.6 The TETON system 
The used TETON system consisted of two vectors pREVTETON (Clonetech) and 
pREVTRE-TIGHT. The latter was constructed by former lab member Piotr Kurys by 
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cutting the TIGHT element from the commercially available pTRE-TIGHT and 
pasting it into the pREVTRE construct. pREVTETON express the reverse 
tetracycline-controlled transactivator (rtTA) from CMV promoter. In the presence of 
Tc, or a derivate (e.g. dox), the rtTA binds to a TET-response element (TRE) located 
upstream of a CMV promoter on pREVTET-TIGHT and induces expression of the 
gene of interest inserted downstream of the CMV promoter. The TIGHT element of 
pREVTRE-TIGHT was inserted to ensure less transcription leakage from the vector 
in absence of Tc or dox. pREVTETON and pREVTRE-TIGHT are both retroviral 
vectors containing viral packing signal  (Ψ+) and long terminal repeats (LTR) but lack 
genes for core structural proteins (gag), reverse transcriptase/integrase (pol) and coat 
glycoproteins (env) [168]. Packaging cells (BOSC) expressing these three genes are 
used to produce infectious [169], but replication-incompetent retroviral particles 
which can then be used to infect other cells (see 3.1.10). 
3.1.7 Luciferase assay 
The pREVTRE-LUC (Clonetech) vector has a luciferase reporter gene downstream of 
the TRE controlled CMV promoter. Isolated 3T3-L1 clones were grown to 50-70% 
confluency on 12 well plates and transfected with 250 ng pREVTRE-LUC and 250 
ng carrier DNA followed by 48h of treatment with or without 1µg/mL dox (Sigma) in 
media. Cells were then treated with lysis buffer [25mM Tris-HCl (both from VWR) 
(ph 7.8), 2mM DTT (Sigma), 10% glycerol (Invitrogen), 1% Triton-X (Sigma)], 
harvested and centrifuged at 15 000 g for 2 minutes. Supernatant was measured for 
luciferase activity with Victor2 multilabel counter (PerkinElmer) where reaction 
buffer was added. The luciferase activity given in counts per second (CPS) was 
normalized to the protein concentration of the supernatant and compared to negative 
control.  
3.1.8 cDNA synthesis and quantitative PCR 
RNA was isolated from harvested cells using TRIzol (Invitrogen) and treated with 
DNase I (Ambion). cDNA was generated from 3µg RNA using SuperScript II 
Reverse Transcriptase (Invtrogen). Quantitative Polymerase Chain Reaction (qPCR) 
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was done, to measure cDNA levels of the MKPs and empty vector, using the 
LightCycler 480 system (Roche). In a reaction volume of 10µL 1x LightCycler480 
SYBR Green I Master mix (Roche), 0.5µM of each primer and 1µL of cDNA 
template was mixed. Negative controls without template or with RNA, were also 
included in the reaction. The qPCR reaction was initialized with a 10 minutes enzyme 
hot-start/template denature step at 95°C. Next the reaction went through 40 cycles of 
95°C denaturation for 10 seconds, primer dependent temperature (see Table 2) of 
annealing for 10 seconds, and 72°C extension for 20 seconds. The last cycle was 
followed by a melting curve analysis to ensure that a reaction free of byproducts had 
been performed. Dilution standard curves were used as external standards. The level 
of fluorescence emitted from SYBR Green dye when incorporated in double-stranded 
DNA, was detected in each cycle by the LightCycler 480 instrument. The crossing 
point (CP) values, defined as the point which the fluorescence increased appreciably 
above the background, gave values correlating to the total amount of cDNA in each 
of the samples. The CP values were used to calculate the relative expression of the 
genes of interest, comparing their values to those of the empty vector samples. All 
gene quantities were normalized to the murine housekeeping gene 36B4. Raw data 
were compiled with LightCycler 480 instrument software (Roche) and further data 
analyses were performed with Office Excel 2007 (Microsoft). 




Forward: 5´-cgtctgtggctcaggacatc-3´ mVHR 
Reverse: 5´-cattgagctggcagagttgg-3´ 
62 439 
Forward: 5´-ggctagcatgactggtgga-3´ hisMKP6  
Reverse: 5´-atgcctcctatgtctccc-3´ 
62 150 
Forward: 5´-caaggatctgatgacccaaa-3´ mVH5 
Reverse: 5´-cggctctcacagatgaagtc-3´ 
64 87 
Forward: 5´-aagcgcgtcctggcattgtct-3´ 36B4 
Reverse: 5´-ccgcaggggcagcagtggt-3´ 
62 136 
Table 2. Primers used in qPCR with sequences, annealing temperatures and product lengths. All primers 
were purchased from Sigma.  
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3.1.9 Western analysis 
Protein extracts were obtained from harvested cells by resuspending the cells in lysis 
buffer [0.5mM DTT, 20mM β-glycerol phosphate, 0.1mM NaVO3, 2µg/mL 
Leupeptin, 1mM phenylmethylsulphonyl-fluoride (PMSF), 0.2M Hepes (pH 7.7), 3M 
NaCl, 2mM EDTA, 1% Triton-X, 15mM MgCl2 (all from Sigma)] and rotating at 
4°C overnight, followed by centrifugation at 15 000g for 20 minutes, 4°C. Prot
concentration was measured with Victor
ein 
2 multilabel counter using Bio-Rad protein 
assay. Samples of 70µg protein were mixed with reducing SDS-buffer [187.5mM 
Tris-HCl (ph 6.8), 6% SDS (Fluka), 30% glycerol, 0.03% phenol red (Sigma), 1.25M 
DTT] and resolved through 10 % or 12% SDS-PA Gel. A Precision Plus Protein dual 
color ladder marker (Bio-Rad) determined the molecular weight of the bands. The 
proteins were transferred from the gel to a PVDF membrane (Bio-Rad). The 
membrane was blocked with 5% dry skimmed milk in TBST solution [Tris Buffered 
Saline (ph 7.4), 0.1% Tween (Sigma)] and incubated with primary antibody in TBST 
containing 5% BSA and 0.04% sodiumazide (Sigma) over night at 4°C. Primary 
antibodies used: anti (α)- His-tag mouse monoclonal antibody (1:5000 dilution, 
Clonetech), α-β-actin mouse monoclonal antibody (1:10000, Sigma), α-VHR rabbit 
polyclonal antibody (1:1000,), α-DUSP14 (MKP6 human homolog) goat polyclonal 
antibody (1:1000, abcam) , α-DUSP8 (VH5 human homolog) goat polyclonal 
antibody (1:1000, abcam), α-aP2 rabbit polyclonal antibody (1:2000, generous gift 
from Gökhan Hotamisligil), α-phospho-ERK rabbit polyclonal antibody (1:1000, Cell 
Signaling) , α-total ERK rabbit polyclonal antibody (1:1000, Cell Signaling). The 
membrane was incubated with secondary antibody in 5% milk TBST for 1 hour at 
room temperature. Secondary antibodies used: horseradish peroxidise-conjugated 
(HRP) α-mouse IgG antibody (1:5000, Sigma), HRP α-rabbit IgG antibody (1:10000, 
Sigma), HRP α-goat IgG antibody (1:8000, Santa Cruze Biotechnology). ECL 
Western blotting detection reagents and analysis system were utilized for the 
immunoreactive bands according to the manufacturer’s (GE Healthcare) instructions. 
For quantification, Western blots were digitalized with scanner machine (Epson 
Perfection V700 Photo) and optical density was measured with the software 
ImageQuant TL (Amersham Biosciences).  
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3.1.10 Retrovirus production and infection 
Virus packing BOSC cells were transfected with pREVTETON, pREVTRE-TIGHT, 
or pREVTRE-TIGHT His-VHR using Fugene 6. 48 hours after transfection virus 
containing media were collected and filtered through 0.45µm sterile filter. ~60% 
confluent 3T3-L1 cells grown for 14-18 hours were infected with a mix of 2 parts 
virus containing medium, 1 part standard medium, mixed with polybrene to a total 
concentration of 4µg/mL and incubated for 24 hours, after which cells were changed 
to standard medium and incubated for additional 48 hours. 3 days after infection start, 
cells were subjected to selection treatment (1000µg/mL G418 for pREVTETON 
infection of 3T3-L1 and 500 µg/mL G418 plus 300µg/mL Hygromycin for 
pREVTRE-TIGHT/pREVTRE-TIGHT His-VHR infection of 3T3-L1 TETON stable 
cell line) for 3 weeks. Healthy looking colonies were picked and expanded separately 
with half selection treatment. 
3.1.11 Statistics 
Statistical analyses were performed using the T-test in MS Excel. Values of p < 0.05 
for 2-tailed T-test were considered significant. 
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4. Results 
4.1 Regulation of VHR protein expression during 3T3-L1 
differentiation 
Previous finding in the Saatcioglu group have shown that several MKPs are regulated 
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Figure 5. MKP mRNA levels during differentiation of 3T3-L1 cells. 3T3-L1 cells were induced to 
differentiate and harvested at indicated timepoints. Total RNA was isolated, converted to cDNA and expression 
of VHR (A), MKP6 (B) and VH5 (C) mRNA were measured by qPCR described in Materials and Methods. 
mRNA levels were normalized to 36B4 mRNA and are presented relative to day -2 samples. The results 
presented are the average of three independent experiments. * indicates significance compared to day -2 
samples, p < 0.05, n = 9.   
To confirm the significance of these data we chose the three most significantly 
regulated MKPs, VHR, MKP6 and VH5, for further studies. 3T3-L1 cells were 
induced to differentiate and harvested at time-points as shown in Figure 6B and C. 
Since there is a report indicating MKP1 action in hypertrophied 3T3-L1 cells [167], 
we additionally looked at protein levels in the hypertrophied state. Differentiation 
was confirmed by Oil Red O staining of TG accumulated in developed (day 8) and 
hypertrophied (day 21) adipocytes (Figure 6A). Unfortunately, due to problems with 
antibodies for MKP6 and VH5 no conclusive results on endogenous protein levels 
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during adipogenesis could be obtained. However, Figure 6B shows quantification 
from Western analysis with VHR antibody from two separate differentiation 
experiments. VHR expression is significantly downregulated up to day 6 followed by 
a significant upregulation into the hypertrophied state at day 16. Figure 6C shows a 
representative Western blot for VHR expression with β-actin levels as loading 
control. We therefore conclude that VHR expression is downregulated in the 
beginning stages of differentiation up to day 6, but upregulated thereafter exceeding 
the day 0 levels at day 12, and reaching maximal levels by day 16. These data are 




























Day -2 0 2 4 6 8 12 16 21
Day -2 0 2 4 6 8 12 16 21
 
Figure 6. VHR protein levels during 3T3-L1 differentiation. Proliferating 3T3-L1 cells (-2) were grown to 
confluency. Two days post confluency (0) cells were subjected to induction medium described in Materials and 
Methods and then stained with Oil Red O or harvested at indicated timepoints. Harvested cells were subjected 
to protein extraction for Western analysis. A: Differentiation status was verified with Oil Red O staining, 
displaying mature (day 8) and hypertrophied (day 21) 3T3-L1 cells magnified 1X and 200X. B: Four separated 
Westerns analysis for VHR expression, obtained form two independent differentiation experiments were 
quantified by optical density described in Materials and Methods. The quantified data were normalized to 
quantification of β-actin levels for corrensponding timepoint and are presented relative to day -2. * indicate 
significance, p < 0.05, n = 4, except day 21 with n = 1. C: A representative blot for the four Western analyses 
probed for VHR antibody is indicated (eVHR). β-actin was used as loading control. 
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4.2 Ectopic expression of MKPs  
In order to study the functional role of the three MKPs chosen, we constructed 
mammalian expression vectors for them. VHR and MKP6 vectors were made by 
other lab members while VH5 cloning was part of this work. For all vectors the MKP 
open reading frame was cloned into the pcDNA4 expression vector with a His tag in 
the 5’ end to facilitate its detection in further applications. The His-MKP fragment 
was then transferred to a pRevTRE-TIGHT construct which enables retroviral 
expression in a Tc inducible manner. Tc-inducible systems require the simultaneous 
expression in the same cell of the Tc-dependent Activator protein along with the Tc 
(dox)-inducible constructs [170]. 
To confirm successful construction of the various MKP constructs, 3T3-L1 and COS-
7 cells were transiently transfected with either a pcDNA4 MKP or a pRevTRE-
TIGHT His-MKP, referred to as pcMKP and tetMKP, respectively, from now. Figure 
7A shows the mRNA levels of ectopically expressed VHR in 3T3-L1 cells in which 
expression was approximately 15-fold higher in the pcDNA4 compared with the 
TETON system. Treatment with dox induced 3T3-L1 tetVHR ~9-fold compared to 
non-treated cells. Leakage from the TETON system is a common problem [171] but 
that does not seem to be the case here. Western analysis with a His antibody shows 
that protein expression correlates with mRNA expression in both 3T3-L1 cells 
(Figure 7B) and COS-7 cells (Figure 7C) confirming that both constructs are 
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Figure 7. Ectopic expression of VHR in 3T3-L1 and COS-7 cells. 3T3-L1 and COS-7 cells were transfected 
with pcVHR, tetVHR+rtTA, empty vector or left untransfected (N). Cells were then incubated with or without 
dox as indicated. Cells were harvested, mRNA or protein extracts were prepared, and were used in qPCR or 
Western analysis. A: mRNA expression of VHR in 3T3-L1 cells was determined by qPCR as detailed in 
Materials and Methods. Levels were normalized to 36B4 mRNA and are presented relative to empty vector. * 
indicates significance, p < 0.05, n = 3. B: Expressed His-VHR protein was detected by Western analysis of 
3T3-L1 whole cell extracts probed for His antibody. An unspecific band used as loading control is indicated 
(unspecific). C: Expressed His-VHR protein was detected by Western analysis of COS-7 whole cell extracts 
probed for His antibody. An unspecific band used as loading control is indicated (unspecific). 
A similar analysis was carried out for MKP6 as shown in Figure 8. As with VHR, 
pcMKP6 construct gave rise to significantly higher mRNA expression, approximately 
60-fold more than that observed with tetVHR. Nevertheless, there was strong dox 
regulation of VHR expression from tetVHR with a 14 fold upregulation in the 
presence of dox. Figure 8B verifiy that the His antibody recognizes the expressed 
His-MKP6 protein. While ending this work, a new commercial antibody against 
human DUSP14 became available. According to manufacturer, sequence alignment 
indicated that this antibody may also have specificity against the murine MKP6. 
Figure 8C and D show both the transfected and endogenous MKP6 detected with this 
antibody. pcMKP6 expression is high and the dox induced tetMKP6 is apparent. No 
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visible band is seen without addition of dox. As seen with the VHR constructs, the 
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Figure 8. Ectopic expression of MKP6 in 3T3-L1 and COS-7 cells. 3T3-L1 and COS-7 cells were transfected 
with pcMKP6, tetMKP6 + rtTA, empty vector or left untransfected (N). Cells were then incubated with or 
without dox as indicated. Cells were harvested, mRNA or protein extracts were prepared, and were used in 
qPCR or Western analysis. A: mRNA expression of His-MKP6 in 3T3-L1 cells was determined by qPCR as 
detailed in Materials and Methods. Levels were normalized to 36B4 mRNA and are presented relative to empty 
vector. * indicates significance, p < 0.05, n = 3. B: Expressed His-MKP6 protein was detected by Western 
analysis of COS-7 cell extracts probed for His antibody. An unspecific band used as loading control is 
indicated (unspecific). C: Ectopically expressed (His-MKP6) and endogenous expressed (eMKP6) MKP6 was 
detected by Western analysis of 3T3-L1 cell extracts probed for DUSP14 antibody. β-actin was used as loading 
control. D: Ectopically expressed (His-MKP6) and endogenous expressed (eMKP6) MKP6 was detected by 
Western analysis of COS-7 cell extracts probed for DUSP14 antibody. β-actin was used as loading control. 
A similar analysis was carried out for VH5 as shown in Figure 9. As with VHR and 
MKP6, the pcVH5 construct gave rise to significantly higher mRNA expression, 
approximately 10-fold more than that observed with tetVH5. There was strong dox 
regulation of VH5 expression from tetVH5 with a 7-fold upregulation in the presence 
of dox. The His antibody that was used for VHR and MKP6 (Figure 7 and 8) has 
proved difficult to use against His-VH5 since a strong unspecific band migrated to 
the same area as VH5 (data not shown). As with MKP6, a new antibody against 
human DUSP8 recently became available and was predicted, by manufacturer, to 
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bind murine VH5 as well. Figure 9B shows that both pcVH5 and tetVH5 specify 
expression of His-VH5 in COS-7 cells. Due to high unspecific binding, an 
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Figure 9. Ectopic expression of VH5 in 3T3-L1 and COS-7 cells. 3T3-L1 and COS-7 cells were transfected 
with pcVH5, tetVH5+rtTA or empty vector. Cells were then incubated with or without dox as indicated. Cells 
were harvested, mRNA or protein extracts were prepared, and were used in qPCR or Western analysis. A: 
mRNA expression of VH5 in 3T3-L1 cells was determined by qPCR as detailed in Materials and Methods. 
Levels were normalized to 36B4 mRNA and are presented relative to empty vector. * indicates significance, p 
< 0.05, n = 3. B: Expressed His-VH5 protein was detected by Western analysis of COS-7 cell extracts probed 
for DUSP8 antibody. β-actin was used as loading control.  
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4.3 Establishment of a stable 3T3-L1 TETON cell line 
In order to induce expression of any protein of interest at any time during 
differentiation of 3T3-L1cells we decided to use the TETON system. As shown 
above, this system was functional in 3T3-L1 cells in transient transfection assays. To 
generate a stable TETON 3T3-L1 cell line, we infected 3T3-L1 cells with retrovirus 
packed in BOSC cells transfected with the pRevTetON vector that specifies 
expression of the rtTA protein. High transfection efficiency (80-90%) of BOSC cells 
was obtained (data not shown) indicating good virus production. After infection, the 
cells were subjected to selection with G418. 48 colonies formed under this selection 
over a period of 3 weeks were picked and expanded, 41 clones proved viable. Clone 
numbering started at 25 to prevent mix-up with sample data from earlier attempts to 
establish 3T3-TETON cell line in the group. Expanded clones were screened for dox 
responsiveness using a luciferase reporter assay in which the expression of luciferase 
is under the control of TRE binding sites [172]. Results from selected clones are 
shown in Figure 10A which indicated that clone #26 was a possible 3T3-L1 TETON 
stable cell line, with a dox-induced activity of ~6 times higher than that of the non-
induced cells. The 3T3-L1 TETON clone #26 will from now on be referred to as 3T3-
tetON26.  
Luciferase activity of non-induced controls in Figure 10A was high for all clones 
compared to the induced and in a few cases higher (most likely caused by a 
combination of leakiness and unstable transfection efficiency). In an attempt to 
reduce the background luciferase expression in non-induced cells, Tc depleted 
medium was used in an independent experiment to confirm the initial results from 
Figure 10A. In addition, different amounts of luciferase vector were used for 
optimization. Data presented in Figure 10B correlates with the results of Figure 10A, 
with a significant (p < 0.05) increase of luciferase activity for dox treated cells when 
250 ng of luciferase vector was used. Transfecting cells with 50 ng luciferase vector 
seemed inefficient as activity for both induced and non-induced cells were low. Using 
100 ng of luciferase vector gave a bit lower un-induced response and higher dox-
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induced response than the 250 ng transfection, but great difference in the induced 
luciferase activity, making it non-significant. In summary, we estimate that the 3T3-
tetON26 clone has 3.5–6 fold inducibility when treated with dox. Although this is 
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Figure 10. Screening of 3T3-L1 TETON clones. A: Represented clones were grown to 50-70% confluency on 
12 well plates with standard media and transfected with 250 ng pREVTRE-LUC and 250 ng carrier DNA and 
treated with or with out dox. Untransfected cells were used as negative control (N). Cells were treated with 
lysis buffer, harvested and subjected to luciferase assay analysis described in Materials and Methods. The 
graphs present an average of the measured luciferase activity from 2 separate transfections set relative to 
negative control. B: Clone 26 cells were grown to 70% confluency on 12 well plates with Tc depleted media 
and cotransfected with 50 ng, 100 ng or 250 ng pREVTRE-LUC indicated (LUC) and carrier DNA to a total of 
500 ng. Untransfected cells were used as negative control (N). Cells were treated with or without dox, treated 
with lysis buffer, harvested and subjected to luciferase assay analysis. Luciferase activity of dox induced cells 
was set reative to activity of negative control. * indicate significance, p < 0.05, n = 3. 
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4.4 Establishment of a stable 3T3-L1 TETON TRE-TIGHT 
His-VHR cell line 
Having made an inducible 3T3-L1 TETON cell line, we first set out to make an 
inducible cell line for His-VHR. 3T3-tetON26 cells were infected with retrovirus 
harboring the tetVHR vector. 15 colonies were picked and expanded. Only 8 clones 
were viable. These were screened for His-VHR expression by Western analysis. 
Figure 11A shows the initial screen of 4 of the 8 clones. 3T3-tetON26 tetVHR8 
(VHR8 in Figure 11A) showed expression levels similar to expression with pcVHR. 
This clone is named 3T3-tetVHR8. Expression in the non-induced cells were low and 
expression in all the other clones were absent, with the exception of VHR5, where 
low level of VHR was detected in the presence of dox.  
To confirm these initial findings, and to compare the induced expression of His-VHR 
relative to endogenous VHR expression, 3T3-tetVHR8 cells were cultured with or 
without dox. Total cell protein extracts were prepared and subjected to Western 
analysis with a VHR antibody (Figure 11B). In this experiment the inducibility of 
tetVHR was lower than in the first experiments (Figure 11A). Furthermore, 
expression of His-VHR was lower than the endogenous VHR (eVHR). Surprisingly, 
endogenous VHR expression in the 3T3-tetVHR8 cells was markedly increased 
compared with the negative and the positive control cell lines.  
To check whether the elevated endogenous VHR levels are transient in 3T3-tetVHR8 
cells, a third check of dox inducibility was done after 5 passages. In addition, both Tc 
depleted medium and standard medium were used to look for an effect in the non-
induced expression of His-VHR. We also transiently transfected the 3T3-tetVHR8 
cells with either tetVHR or pRevTetON in an attempt to increase in His-VHR 
expression increasing rtTA or tetVHR gene. A potential increase compared to the 
dox-treated 3T3-tetVHR8 cells could indicate that one of the virally introduced genes 
had stunted transcription. Figure 11C shows that endogenous levels of VHR in the 
VHR8 clone is still considerably higher than in the original 3T3-L1 cell (E). The His-
VHR expression is still inducible and no apparent difference in the use of Tc depleted 
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medium compared with standard medium is observed. Transient transfection of 3T3-
tetVHR8 did not affect the expression of His-VHR. We thus conclude that with 
higher expression of endogenous VHR than induced His-VHR, the 3T3-tetVHR8 
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Figure 11. Screening of 3T3-L1 TETON TRE-TIGHT VHR clones. A: Whole cell extracts were prepared 
from representative clones (VHR5-8) grown to 50-70% confluency and induced with dox and used in Western 
analysis with a His antibody. An unspecific band used as loading control is indicated (unspecific). P indicates 
extracts prepared from 3T3-L1 cells transfected with pcVHR. B: VHR8 cells were grown to ~70% confluency 
and were either left untreated or treated with dox. Whole cell extracts were prepared and subjected to Western 
analysis with VHR antibody (eVHR indicates endogenous VHR and His-VHR indicates induced expression). 
An unspecific band used as loading control is indicated (unspecific). P indicates extracts prepared from 3T3-L1 
cells transfected with pcVHR. N indicates extracts prepared from 3T3-L1 cells transfected with an empty 
vector. C: VHR8 cells were grown to ~70% confluency in Tc depleted (Tc-) or standard medium and were 
either left untreated or treated with dox. Whole cell extracts were prepared and subjected to Western analysis 
with VHR antibody (eVHR indicates endogenous VHR and His-VHR indicates induced expression). Antibody 
against β-actin was used as loading control. T = VHR8 ectopic expressing pRevTRE-TIGHT 6HisVHR. O = 
VHR8 ectopic expressing pRevTetOn and. E = 3T3-L1 empty vector. 
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4.5 ERK activation immediately after induction of 
differentiation. 
Prior to this work one publication has investigated the early dynamics of ERK 
phosphorylation in differentiation of 3T3-L1 cells [119]. We wanted to confirm these 
data. 3T3-L1 cells were induced to differentiate and were harvested at different 
timepoints before and after induction. Whole cell extracts were prepared and 
subjected to Western analysis with antibodies recognizing phosphorylated ERK and 
total ERK (Figure 12). There was a quick burst of phosphorylation of ERK 
immediately after induction. Phosphorylation started to diminish within 30 minutes 
after induction and is heavily reduced after 2 hours. Worth noting is the slightly 
elevated ERK2 phosphorylation after 12 hours. These findings are in general 
agreement with previously published data [119], although the phosphorylation burst 
that they observe after after 12 hours is stronger. In the un-induced growth arrested 
3T3-L1 cells (timepoint 0) we observed ERK activation compared to proliferating 
cells (timepoint -2). This deviated from what was previously reported where there 
low ERK activity and no phosphorylation differences between growth arrested and 
proliferating cell was seen [119]. We do not know the basis for these minor 
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Figure 12. ERK1/2 activity in 3T3-L1 cells after induction of differentiation. Proliferating 3T3-L1 cells (-2d) 
were grown to confluency. Two days post confluency (0) cells were subjected to induction medium (described in 
Materials and Methods) and then harvested at indicated timepoints (m = minutes, h = hours, d = days). Whole 
cell extracts were prepared and subjected to Western analysis with phopho-ERK antibody (phERK indicates 
phosphorylation levesl of ERK1 and ERK2, upper and lower bands respectively). Total ERK levels are used as 
loading control (ERK).  
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4.6 His-VHR overexpression prior to and during 3T3-L1 
differentiation 
Since the 3T3-tetVHR8 clone had significantly elevated endogenous levels of VHR, 
we decided to study the impact of VHR expression on MAPK phosphorylation by 
transiently transfection of pcVHR into 3T3-L1 cells. pcVHR or an empty expression 
vector were transfected into 3T3-L1 cells which were then differentiated. Cells were 
harvested at different timepoints and whole cell extracts were prepared and subjected 
to Western analysis with different antibodies. Un-transfected 3T3-L1 cells were used 
as control of final differentiation status. 
As shown in Figure 13B, there were no observable differences in differentiation 
status of the VHR overexpressing 3T3-L1 cells compared with empty vector 
transfected or untransfected cells assessed by Oil Red O staining. Furthermore, there 
was similar aP2 expression (Figure 13A) in cells transfected with pcVHR and cells 
transfected with empty expression vector demonstrating that VHR does not affect the 
final differentiation status of the 3T3-L1 cells. Examination of ectopically expressed 
His-VHR indicated that it is present until day 8 although it weakens considerably 
during the course of differentiation as would be expected from a transiently expressed 
protein. There were no differences ERK phosphorylation for the His-VHR 
overexpressing cells and the cells transfected with empty vector (Figure 13A), 
indicating that VHR has no effect on ERK phosphorylation in 3T3-L1 cells. The 
trend for phosphorylation of ERK is similar in Figure 13A to that of Figure 12 with a 
quick transient burst seen immediately after induction. However, we clearly see some 
differences when comparing the empty expression vector transfected cell (Figure 
13A) with the untransfected cell (Figure 12): the transfected proliferating 3T3-L1 
cells (day -2) display much more phosphorylation than that in non-transfected cells; 
the opposite is observed in ERK activation in day 0. Furthermore, transfected cells in 
Figure 13A appear to maintain ERK phosphorylation longer after induction with 
equal levels of phosphorylation at timepoints 30 minutes and 2 hours, whereas in 
untransfected cells the 2 hour phosphorylation is lower than that at 30 minutes. This 
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may indicate an effect of the transfection scheme on ERK phosphorylation which 
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Figure 13. Overexpression of His-VHR prior to and during 3T3-L1 differentiation. 60% confluent 3T3-L1 
cells were transfected first three days and secondly 12 hours prior to transfection with pcVHR (+) or empty 
vector (-) described in Materials and Methods. Cells were induced to differentiate two days after reached 
confluency and then harvested at indicated timepoints or stained with Oil Red O. A: Whole cell extracts were 
prepared from the indicated timepoints (m = minutes, h = hours, d = days) and used in Western analyses with 
VHR antibody (eVHR indicates endogenous VHR and His-VHR indicates induced expression). Western 
analysis with phospho-ERK antibody (phERK) indicates phosphorylation levels of ERK1 and ERK2, upper and 
lower bands respectively. Total ERK levels are used as loading control (ERK). Differentiation of His-VHR 
expressing cells and empty vector transfected cells were compared by Western analysis with aP2 antibody. B: 
Differentiation status of pcVHR and empty vector transfected and untransfected (Negative) cells 8 days post 
induction, were compared with Oil Red O staining.  
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5. Discussion 
In this study, we have found that regulation of VHR protein expression during 
adipogenesis correlates with what we have observed earlier for mRNA levels (Figure 
5A and 6B and C). VHR levels are down regulated at day 4-6 compared to the pre-
adipogenic state and rise as the 3T3-L1 cells develop into mature adipocytes at day 8. 
Further culturing of the adipocytes leads to hypertrophy observed with an increase of 
lipid droplet size (Figure 6A) [167]; interestingly, VHR levels continue to rise into 
the hypertrophied state (Figure 6B and C). No data is yet obtained for MKP6 or VH5 
regulation during adipogenesis at the protein level due to lack of a functional 
antibody during the course of this study. Work is in progress to optimize the 
conditions to use the available antibodies to detect endogenous MKP6 andVH5 (see 
below)  
Through ectopic expression we have confirmed that the constructs for overexpression 
of the VHR, MKP6 and VH5 are transcribed into mRNAs and translated into proteins 
(Figure 7-9). These experiments also indicated that the human DUSP14/MKP6 and 
DUSP8/VH5 antibodies could be used as probes against the murine MKP6 and VH5 
proteins, respectively (Figure 8C, 8D and 9B). We have found the conditions for the 
MKP6 antibody to get a distinct specific band also for endogenous MKP6 in 3T3-L1 
cells (Figure 8C) which can now be used to investigate a possible regulation of the 
MKP6. On the other hand, we have not yet observed VH5 protein expression in 3T3-
L1 cells. This may indicate a posttranscriptional regulation of VH5 in 3T3-L1 cells 
which results in the loss of the epitope that was used to raise the antibody, but is more 
likely to be low transfection efficiency and/or lack of specificity of the antibody 
(Figure 9B).  
There are large differences in the expression of the MKPs from the pcDNA4/HISMax 
vector and the pRevTRE-TIGHT vector, especially observed for mRNA, reaching a 
100-fold difference (Figure 7A-9A). These differences could be due to a combination 
of several factors. For example, the pcDNA4 MKP transfection experiments were 
performed with double the amount of expression vector compared with pREVTRE-
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TIGHT transfections. In addition, the promoters that drive the expression of the 
MKPs in the two vectors are different (Figure 4).  
By use of retroviral infection, we established a stable cell line expressing the rtTA 
factor (3T3-tetON26), confirmed by a luciferase reporter assay (Figure 10A and B). 
The fold induction of luciferase activity was less than what we observed with the 
transient expression studies (Figure 7A-9A). Nevertheless, we decided to work 
further with this clone, as the luciferase vector used in the luciferase assay lack the 
TIGHT element that is present in the tetMKP. 
The second retroviral infection of the 3T3-tetON26 cell line resulted in a stable cell 
line able to induce expression of His-VHR in the presence of dox (3T3-tetVHR8, 
Figure 11A). Unfortunately, further tests of the 3T3-tetVHR8 revealed that His-VHR 
was also expressed without dox induction (Figure 11B and C). In addition, compared 
with wild type 3T3-L1 cells, endogenous VHR expression has been chronically 
elevated to a level higher than the induced expression of His-VHR (Figure 11B and 
C). The leaky His-VHR expression and the elevated endogenous VHR levels made 
this cell line not suitable for further investigations of VHR in 3T3-L1 adipogenesis. 
These findings made it necessary to recheck the endogenous levels of VHR in the 
3T3-tet26 cell line to find out if the elevated levels of VHR were caused by the 
process of introducing His-VHR with retrovirus or in the first infection. Data not 
presented here show an increase in the endogenous levels of VHR in 3T3-tetON26 
cells. This suggests that the process of infecting 3T3-L1 cells lead to elevated 
endogenous VHR levels. One possibility is that the isolated 3T3-tetON26 clone itself 
had higher VHR levels than the rest of the cell pool prior to infection for unknown 
reasons. This can be elucidated by comparing the endogenous VHR expression of the 
3T3-tetON26 clone to other isolated clones from the same infection. Another scenario 
is that the selection of the 3T3-tetON cells with G418 was too high and stressed the 
cells to alter their VHR expression pattern. Earlier attempts in the group to establish a 
3T3-L1-tetON cell line have used lower concentrations of G418 and could therefore 
be compared with 3T3-tetON26 cells to see if the selection scheme itself has an effect 
on VHR expression in the 3T3-L1 cells. The higher selection used in this study was 
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based on experience in previous selections where a large proportion of the picked 
colonies was false positive. Also higher selection tended to give greater rtTA 
expression in true positive stable clones. 
Two previous studies have found early activation of ERK in 3T3-L1 cells after 
induction [119, 123]. Both publications report an immediate activation of ERK, 
followed by a rapid decline. Our data are largely in agreement with these findings 
(Figure 12 and 13A); there are, however, some differences. Figure 12 shows little 
ERK phosphorylation at day -2 and an incremental increase just prior to induction. 
Figure 13A displays quite high ERK phosphorylation at day -2 and a clear reduction 
at day 0. We do not know the basis for these differences. A recent publication 
showing that cationic lipids can induce ERK phosphorylation [173] support the 
hypothesis that the transfection reagent that was used itself could be the cause of the 
differences observed when comparing phospho ERK levels in Figures 12 and 13A. In 
contrast, previous studies display equal levels in ERK phosphorylation in 
proliferating and post confluent 3T3-L1 cells [119, 123]. These differences could be 
caused by cell line deviations, or indicate fluctuating ERK phosphorylation in 
proliferating cells which is abolished when cells go into growth arrest. Following this 
hypothesis, our post confluent cells (day 0) in Figure 12 may not have entered growth 
arrest completely and this could explain the elevated ERK phosphorylation compared 
to cells in Figure 13A (day 0).   
ERK and JNK have been found as substrates for dephosphorylation by VHR both in 
vitro and in vivo [155, 174, 175]. VHR also has a proposed role in cell cycle 
progression [158], making it highly interesting to study its possible role in 
adipogenesis. Ectopic expression of VHR alone does not affect ERK phosphorylation 
during adipogenesis of 3T3-L1 cells (Figure 13A). Neither does the ectopic expressed 
VHR affect the lipid accumulation and aP2 expression, both markers of 
differentiation (Figure 13A and B). One could argue that the tagged VHR that we 
express does not have wild type enzymatic activity. For example, the His tag at the 
N-terminus of VHR could potentially inhibit its phosphatase activity. However, 
earlier reports have shown that an HA-tag at the N-terminus, a much larger tag, did 
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not affect VHR enzyme activity [155], and thus this is unlikely to be the reason for 
the lack of effect of VHR expression on ERK activity in 3T3-L1 cells. Another 
possibility is that lack of appropriate activators of VHR in 3T3-L1 cells hinders its 
activity on ERK. For example, VRK3 and Zap-70 have been identified as activators 
of VHR necessary for ERK dephosphorylation [156, 157]. It is possible that one or 
both of these factors is lacking or dimished in 3T3-L1 cells and that is the basis for 
lack of VHR activity towards ERK. 
It should be considered that VHR may still exert effects in adipocytes or developing 
adipocytes without affecting aP2 expression and lipid accumulation. The elevated 
VHR levels from day 8 to day 21 of 3T3-L1 differentiation (Figure 6B and C) could 
suggest a role in hypertrophied state of these cells. Other targets of VHR, both known 
and unknown, may be modified and may contribute to this phenotype. For example, 
VHR overexpression can affect JNK activity which should definitely be checked 
since JNK activation is associated with hypertrophy of adipocytes, but not 
adipogenesis per se [122, 133]. The role of VHR in cell cycle regulation is also 
relevant here since in adipogenesis proliferation and growth arrest play important 
roles [53, 61]. Although overexpression may not particularly affect the cell cycle, 
knockdown experiments (using siRNA) or inactivation (using inhibitors) of VHR in 
3T3-L1 cells would make it possible to investigate its role in adipogenesis.  
With the constructs and antibodies for MKP6 and VH5 in places (VH5 antibody 
needs some more optimization), similar analysis on them can be performed. To 
investigate the overexpression of MKPs in the later stages of adipogenesis of 3T3-L1 
cells or in hypertrophied state, transient transfection would be inefficient. A new 
attempt to establish a TETON 3T3-L1 cell line is warranted that gives a larger fold 
increase in response to dox. To our knowledge, there are no reports to date of a 
successfully established 3T3-L1 TETON cell line. Two groups have used the TetOFF 
system (opposite of TETON: Tc/dox inhibits expression) in 3T3-L1 cells [176, 177] 
and this can be adopted. Another alternative could be establishing a 3T3-L1 cell line 
stably expressing the coxsackievirus and adenovirus receptor (CAR) which enhance 
the transduction efficiency of the cell line for adenovirus [178, 179] that would make 
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these cells amenable for adenoviral transduction. Finally, generation of VHR 
knockdown mice, especially those in which the knockdown is targeted in fat tissue, 
would be a very useful experiments to conclusively assess the role of VHR in 
adipogenesis. 
In summary, the data presented here suggest that VHR may have a role in 
adipogenesis. Further studies, involving both overexpression and knockdown of 
VHR, as well as the other MKPs that we have found to be distinctly regulated during 
the adipogenic conversion of 3T3-L1 cells, are warranted. 
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